Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Chellappa, Stalin ^a,b   Hugenschmidt, Harald ^a   Hagness, Morten ^a,b   Line, Pål D ^a   Labori, Knut J ^a   Wiedswang, Gro ^a   Taskén, Kjetil ^a,b   Aandahl, Einar M ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

FOXP3; plasticity; regulatory T Cells; ROR t; suppression; surface Markers; Th17 cell; Th2 cell

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CD134 ANTIGEN; CD147 ANTIGEN; CD39 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; PROGRAMMED DEATH 1 RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CELLULAR SECRETION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MAST CELL DEGRANULATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; TH2 CELL; UPREGULATION;

EID: 84962786522     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1102828     Document Type: Article

References (54)

1. S.Sakaguchi, M.Miyara, C.M.Costantino, D.A.Hafler. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500; PMID:20559327; http://dx.doi.org/10.1038/nri2785
2. P.A.Savage, S.Malchow, D.S.Leventhal. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013; 34:33-40; PMID:22999714; http://dx.doi.org/10.1016/j.it.2012.08.005
3. F.Martin, S.Ladoire, G.Mignot, L.Apetoh, F.Ghiringhelli. Human FOXP3 and cancer. Oncogene 2010; 29:4121-9; PMID:20498631; http://dx.doi.org/10.1038/onc.2010.174
4. S.Yaqub, E.M.Aandahl. Inflammation Versus Adaptive Immunity in Cancer Pathogenesis. Crit Rev Oncog 2009; 15:43-63; PMID:20136627; http://dx.doi.org/10.1615/CritRevOncog.v15.i1-2.20
5. R.J.deLeeuw, S.E.Kost, J.A.Kakal, B.H.Nelson. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18:3022-9; PMID:22510350; http://dx.doi.org/10.1158/1078-0432.CCR-11-3216
6. R.Siegel, D.Naishadham, A.Jemal. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
7. J.L.Cameron, T.S.Riall, J.Coleman, K.A.Belcher. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244:10-5; PMID:16794383; http://dx.doi.org/10.1097/01.sla.0000217673.04165.ea
8. A.Westgaard, S.Tafjord, I.N.Farstad, M.Cvancarova, T.J.Eide, O.Mathisen, O.P.Clausen, I.P.Gladhaug. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008; 8:170; PMID:18547417; http://dx.doi.org/10.1186/1471-2407-8-170
9. V.Sandhu, I.M.Bowitz Lothe, K.J.Labori, O.C.Lingjaerde, T.Buanes, A.M.Dalsgaard, M.L.Skrede, J.Hamfjord, T.Haaland, T.J.Eide et al. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol 2015; 9:758-71; PMID:25579086; http://dx.doi.org/10.1016/j.molonc.2014.12.002
10. A.Evans, E.Costello. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012; 3:270; PMID:22969725; http://dx.doi.org/10.3389/fphys.2012.00270
11. Y.Tang, X.Xu, S.Guo, C.Zhang, Y.Tang, Y.Tian, B.Ni, B.Lu, H.Wang. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 2014; 9:e91551; PMID:24637664; http://dx.doi.org/10.1371/journal.pone.0091551
12. T.Yamamoto, H.Yanagimoto, S.Satoi, H.Toyokawa, S.Hirooka, S.Yamaki, R.Yui, J.Yamao, S.Kim, A.H.Kwon. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012; 41:409-15; PMID:22158072; http://dx.doi.org/10.1097/MPA.0b013e3182373a66
13. N.Hiraoka, K.Onozato, T.Kosuge, S.Hirohashi. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34; PMID:17000676; http://dx.doi.org/10.1158/1078-0432.CCR-06-0369
14. F.McAllister, J.M.Bailey, J.Alsina, C.J.Nirschl, R.Sharma, H.Fan, Y.Rattigan, J.C.Roeser, R.H.Lankapalli, H.Zhang et al. Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia. Cancer Cell 2014; 25:621-37; PMID:24823639; http://dx.doi.org/10.1016/j.ccr.2014.03.014
15. N.R.Blatner, M.F.Mulcahy, K.L.Dennis, D.Scholtens, D.J.Bentrem, J.D.Phillips, S.Ham, B.P.Sandall, M.W.Khan, D.M.Mahvi et al. Expression of RORγt Marks a Pathogenic Regulatory T Cell Subset in Human Colon Cancer. Sci Transl Med 2012; 4:164ra59; http://dx.doi.org/10.1126/scitranslmed.3004566; PMID:23241743
16. S.Yang, B.Wang, C.Guan, B.Wu, C.Cai, M.Wang, B.Zhang, T.Liu, P.Yang. Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 2011; 89:85-91; PMID:20952660; http://dx.doi.org/10.1189/jlb.0910506
17. I.Kryczek, K.Wu, E.Zhao, S.Wei, L.Vatan, W.Szeliga, E.Huang, J.Greenson, A.Chang, J.Rolinski et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011; 186:4388-95; PMID:21357259; http://dx.doi.org/10.4049/jimmunol.1003251
18. K.Wang, K.Kim Min, G.Di Caro, J.Wong, S.Shalapour, J.Wan, W.Zhang, Z.Zhong, E.Sanchez-Lopez, L.-W.Wu et al. Interleukin-17 Receptor A Signaling in Transformed Enterocytes Promotes Early Colorectal Tumorigenesis. Immunity; 41:1052-63; PMID:25526314; http://dx.doi.org/10.1016/j.immuni.2014.11.009
19. W.Liu, A.L.Putnam, Z.Xu-Yu, G.L.Szot, M.R.Lee, S.Zhu, P.A.Gottlieb, P.Kapranov, T.R.Gingeras, B.Fazekas de St Groth et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701-11; PMID:16818678; http://dx.doi.org/10.1084/jem.20060772
20. K.S.Voo, Y.H.Wang, F.R.Santori, C.Boggiano, Y.H.Wang, K.Arima, L.Bover, S.Hanabuchi, J.Khalili, E.Marinova et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 2009; 106:4793-8; PMID:19273860; http://dx.doi.org/10.1073/pnas.0900408106
21. M.Ayyoub, F.Deknuydt, I.Raimbaud, C.Dousset, L.Leveque, G.Bioley, D.Valmori. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A 2009; 106:8635-40; PMID:19439651; http://dx.doi.org/10.1073/pnas.0900621106
22. G.Beriou, C.M.Costantino, C.W.Ashley, L.Yang, V.K.Kuchroo, C.Baecher-Allan, D.A.Hafler. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009; 113:4240-9; PMID:19171879; http://dx.doi.org/10.1182/blood-2008-10-183251
23. B.Vizio, A.Novarino, A.Giacobino, C.Cristiano, A.Prati, L.Ciuffreda, G.Montrucchio, G.Bellone. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med 2012; 4:70-8; PMID:23060925; http://dx.doi.org/10.3892/etm.2012.553
24. L.Zhou, J.E.Lopes, M.M.Chong, I.I.Ivanov,, R.Min, G.D.Victora, Y.Shen, J.Du, Y.P.Rubtsov, A.Y.Rudensky et al. TGF-β-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236-40; PMID:18368049; http://dx.doi.org/10.1038/nature06878
25. R.Du, H.Zhao, F.Yan, H.Li. IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J Leukoc Biol 2014; 96:39-48; PMID:24744433; http://dx.doi.org/10.1189/jlb.1RU0114-010RR
26. X.Chen, J.J.Oppenheim. Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol 2011; 11:1489-96; PMID:21635972; http://dx.doi.org/10.1016/j.intimp.2011.05.018
27. L.Cosmi, R.De Palma, V.Santarlasci, L.Maggi, M.Capone, F.Frosali, G.Rodolico, V.Querci, G.Abbate, R.Angeli et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205:1903-16; PMID:18663128; http://dx.doi.org/10.1084/jem.20080397
28. A.L.Bayer, A.Yu, T.R.Malek. Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells. J Immunol 2007; 178:4062-71; PMID:17371960; http://dx.doi.org/10.4049/jimmunol.178.7.4062
29. A.Laurence, C.M.Tato, T.S.Davidson, Y.Kanno, Z.Chen, Z.Yao, R.B.Blank, F.Meylan, R.Siegel, L.Hennighausen et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26:371-81; PMID:17363300; http://dx.doi.org/10.1016/j.immuni.2007.02.009
30. S.Huber, N.Gagliani, E.Esplugues, W.O'Connor, Jr., F.J.Huber, A.Chaudhry, M.Kamanaka, Y.Kobayashi, C.J.Booth, A.Y.Rudensky et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011; 34:554-65; PMID:21511184; http://dx.doi.org/10.1016/j.immuni.2011.01.020
31. A.Chaudhry, R.M.Samstein, P.Treuting, Y.Liang, M.C.Pils, J.M.Heinrich, R.S.Jack, F.T.Wunderlich, J.C.Bruning, W.Muller et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011; 34:566-78; PMID:21511185; http://dx.doi.org/10.1016/j.immuni.2011.03.018
32. C.Asseman, S.Mauze, M.W.Leach, R.L.Coffman, F.Powrie. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190:995-1004; PMID:10510089; http://dx.doi.org/10.1084/jem.190.7.995
33. S.M.Wormann, K.N.Diakopoulos, M.Lesina, H.Algul. The immune network in pancreatic cancer development and progression. Oncogene 2014; 33:2956-67; PMID:23851493; http://dx.doi.org/10.1038/onc.2013.257
34. M.Kleinewietfeld, D.A.Hafler. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol 2013; 25:305-12; PMID:24211039; http://dx.doi.org/10.1016/j.smim.2013.10.009
35. M.Veldhoen, R.J.Hocking, C.J.Atkins, R.M.Locksley, B.Stockinger. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-89; PMID:16473830; http://dx.doi.org/10.1016/j.immuni.2006.01.001
36. L.Xu, A.Kitani, I.Fuss, W.Strober. Cutting edge: Regulatory T cells induce CD4+CD25 -Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007; 178:6725-9; PMID:17513718; http://dx.doi.org/10.4049/jimmunol.178.11.6725
37. P.Pandiyan, R.Conti Heather, L.Zheng, C.Peterson Alanna, R.Mathern Douglas, N.Hernández-Santos, M.Edgerton, L.Gaffen Sarah, J.Lenardo Michael. CD4+CD25+Foxp3+ Regulatory T Cells Promote Th17 Cells In Vitro and Enhance Host Resistance in Mouse Candida albicans Th17 Cell Infection Model. Immunity 2011; 34:422-34; PMID:21435589; http://dx.doi.org/10.1016/j.immuni.2011.03.002
38. S.Piconese, G.Gri, C.Tripodo, S.Musio, A.Gorzanelli, B.Frossi, R.Pedotti, C.E.Pucillo, M.P.Colombo. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009; 114:2639-48; PMID:19643985; http://dx.doi.org/10.1182/blood-2009-05-220004
39. N.R.Blatner, A.Bonertz, P.Beckhove, E.C.Cheon, S.B.Krantz, M.Strouch, J.Weitz, M.Koch, A.L.Halverson, D.J.Bentrem et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A 2010; 107:6430-5; PMID:20308560; http://dx.doi.org/10.1073/pnas.0913683107
40. J.R.Huh, M.W.Leung, P.Huang, D.A.Ryan, M.R.Krout, R.R.Malapaka, J.Chow, N.Manel, M.Ciofani, S.V.Kim et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011; 472:486-90; PMID:21441909; http://dx.doi.org/10.1038/nature09978
41. E.A.Engels, R.M.Pfeiffer, J.F.FraumeniJr, B.L.Kasiske, A.K.Israni, J.J.Snyder, R.A.Wolfe, N.P.Goodrich, A.R.Bayakly, C.A.Clarke et al. SPectrum of cancer risk among us solid organ transplant recipients. JAMA 2011; 306:1891-901; PMID:22045767; http://dx.doi.org/10.1001/jama.2011.1592
42. S.Raimondi, P.Maisonneuve, A.B.Lowenfels. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6:699-708; PMID:19806144; http://dx.doi.org/10.1038/nrgastro.2009.177
43. S.H.Chang, S.G.Mirabolfathinejad, H.Katta, A.M.Cumpian, L.Gong, M.S.Caetano, S.J.Moghaddam, C.Dong. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A 2014; 111:5664-9; PMID:24706787; http://dx.doi.org/10.1073/pnas.1319051111
44. T.Iida, M.Iwahashi, M.Katsuda, K.Ishida, M.Nakamori, M.Nakamura, T.Naka, T.Ojima, K.Ueda, K.Hayata et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 2011; 25:1271-7; PMID:21369705; http://dx.doi.org/10.3892/or.2010.1118
45. J.Du, C.Huang, B.Zhou, S.F.Ziegler. Isoform-specific inhibition of ROR α-mediated transcriptional activation by human FOXP3. J Immunol 2008; 180:4785-92; PMID:18354202; http://dx.doi.org/10.4049/jimmunol.180.7.4785
46. M.Lochner, L.Peduto, M.Cherrier, S.Sawa, F.Langa, R.Varona, D.Riethmacher, M.Si-Tahar, J.P.Di Santo, G.Eberl. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med 2008; 205:1381-93; PMID:18504307; http://dx.doi.org/10.1084/jem.20080034
47. K.Siegmund, M.Feuerer, C.Siewert, S.Ghani, U.Haubold, A.Dankof, V.Krenn, M.P.Schon, A.Scheffold, J.B.Lowe et al. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood 2005; 106:3097-104; PMID:16014565; http://dx.doi.org/10.1182/blood-2005-05-1864
48. E.Gallo, S.Katzman, A.V.Villarino. IL-13-producing Th1 and Th17 cells characterize adaptive responses to both self and foreign antigens. Eur J Immunol 2012; 42:2322-8; PMID:22684943; http://dx.doi.org/10.1002/eji.201142227
49. L.Cosmi, L.Maggi, V.Santarlasci, M.Capone, E.Cardilicchia, F.Frosali, V.Querci, R.Angeli, A.Matucci, M.Fambrini et al. Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol 2010; 125:222-30.e4; PMID:20109749; http://dx.doi.org/10.1016/j.jaci.2009.10.012
50. Y.-H.Wang, K.S.Voo, B.Liu, C.-Y.Chen, B.Uygungil, W.Spoede, J.A.Bernstein, D.P.Huston, Y.-J.Liu. A novel subset of CD4+ TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med 2010; 207:2479-91; PMID:20921287; http://dx.doi.org/10.1084/jem.20101376
51. X.Chen, J.J.Oppenheim. Th17 cells and Tregs: unlikely allies. J Leukoc Biol 2014; 95:723-31; PMID:24563509; http://dx.doi.org/10.1189/jlb.1213633
52. G.Gri, S.Piconese, B.Frossi, V.Manfroi, S.Merluzzi, C.Tripodo, A.Viola, S.Odom, J.Rivera, M.P.Colombo et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008; 29:771-81; PMID:18993084; http://dx.doi.org/10.1016/j.immuni.2008.08.018
53. K.Ganeshan, P.J.Bryce. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-β. J Immunol 2012; 188:594-603; PMID:22156492; http://dx.doi.org/10.4049/jimmunol.1102389
54. H.S.Kuehn, M.Radinger, A.M.Gilfillan. Measuring Mast Cell Mediator Release. Curr Protoc Immunol. 2010; Chapter 7:Unit7.38; PMID:21053305; http://dx.doi.org/10.1002/0471142735.im0738s91